ArticleFrontiers in oncology2025
Case Report: Efficacy of preoperative conversion therapy with lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy in an advanced hepatocellular carcinoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advanced hepatocellular carcinoma (HCC) has a poor prognosis. Conversion therapy based on non-surgical local therapy and drug therapy is an effective treatment for unresectable HCC. We report a case of HCC with intrahepatic metastasis and multiple venous tumor thrombi. After nearly 4 months of conversion therapy with lenvatinib, toripalimab combined with hepatic arterial infusion chemotherapy (HAIC), the lesions were significantly reduced, the portal vein tumor thrombus resolved, and the alpha-fetoprotein (AFP) decreased to the normal range. This patient had no serious adverse events during treatment. After a comprehensive assessment of the patient's status, the patient eventually underwent curative surgical resection of the tumor and had a complete response. The successful experience of this case indicates that lenvatinib, toripalimab combined with HAIC has a good prospect as a conversion therapy for HCC with intrahepatic metastasis and multiple venous tumor thrombi.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.